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Blood pressure-independent effect of angiotensin inhibition on vascular
lesions of chronic renal failure. Previous studies in experimental models
of progressive renal failure have shown that the capacity of antihyper-
tensive drugs to protect glomeruli from sclerosis is often unpredictable
from their effect on systemic blood pressure. The present study was
undertaken to ascertain whether this systemic blood pressure-indepen-
dent structure-preserving effect of antihypertensives, particularly angi-
otensin II converting enzyme inhibitors (ACEI), is confined to the
glomerulus or not, as well as whether this effect is mediated via
angiotensin II (Ang H). The following experimental drug regimens were
used in the rat model of subtotal nephrectomy (sNPX): so-called triple
therapy [TRX; a combination of reserpine 5 mg/liter drinking water
(DW), hydralazine 80 mg/liter DW and hydrochlorothiazide 25 mg/liter
DW], or ACE! (either captopril, CPL, 600 mg/liter DW, enalapril,
ENL, 400 mg/liter DW or lisinopril, LSL, 200 mg/liter DW), or a novel
Ang II receptor antagonist (Ang !!R, L- 158,809, 20 mg/liter DW). These
dosages were identified in pilot studies to be the minimum required to
control systemic blood pressure in the early phase up to 12 weeks. In
addition, a separate group was treated with a higher dose of L-158,809
(80 mg/liter DW) with equipotent systemic pressor effect. Treatment
was initiated eight weeks after subtotal nephrectomy following renal
biopsy, and animals were sacrificed at 16 weeks. In ACE! treated rats,
carotid arterial wall thickening (WT), defined as ratio of media thick-
ening to radius of outer vessel wall, was similar to normal age-matched
control (0.073 in all ACE! treated rats, vs. 0.074 in normal control) and
significantly less than with TRX (ratio 0.118) or untreated sNPX (0.130).
Even more remarkably, coronary arteriole WT in ACEI-treated rats
averaged 0.139, a value less than one half and one third of TRX (0.298)
and untreated sNPX control (0.388), respectively. Similar results were
obtained for mesenteric artery WT. These findings were closely paral-
leled by changes of glomerular sclerosis. In untreated sNPX control
rats, glomerular sclerosis increased from biopsy to autopsy specimens
by an average of 458%. Although TRX dampened the degree of increase
in sclerosis to on average 2 12%, this protective effect was far less than
that achieved by ACEI. In the latter, sclerosis increased on average
only 65% from biopsy to autopsy. Although all ACEIs were more
effective than TRX, captopril and lisinopril groups showed greatest
benefit at these doses. Ang hR also protected renal and extrarenal
structures with 34% increase of sclerosis index in low dose and WT
0.088, 0.117 and 0.112, respectively in carotid, mesenteric and coronary
arteries, Higher dose had greater protective effects, although systemic
pressures were comparable to the low dose, The findings indicate that
in minimum dosages required for controlling systemic blood pressures
ACE! and Ang !!R are more potent than other vasodilators in protecting
glomerular structure. This greater structure-preserving potency of
ACEI and Ang !!R is not limited to the glomerulus, but extends to other
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systemic vascular beds, where variable lesions also develop in chronic
renal failure. The similar results with Ang !!R and ACE! further
indicate that the progressive morphological damage of glomerular and
extraglomerular vasculatures in chronic renal failure involves local
action of angiotensin II.
Previous studies using angiotensin II converting enzyme
inhibitors (ACE!) in animal models of chronic renal failure
(CRF) demonstrated that ACEI protect glomeruli from progres-
sive sclerosis, often in degrees far better than one would expect
from their effect on systemic blood pressure [1—8]. In fact,
ACE! was shown to protect glomeruli from sclerosis even in the
absence of appreciable effect on systemic blood pressure [1],
and our recent studies have shown even greater structure-
preserving effect of higher dose of ACE!, beyond that dose
required to normalize hypertension [3]. Although such an effect
not only dependent on blood pressure is not unique to ACE! [21,
ACE! have attracted attention for greater potential clinical use
of high doses, in view of less frequent side effects of hypoten-
sion compared to non-specific vasodilators. When this struc-
ture-preserving effect of ACE! not solely attributable to blood
pressure control was first noted by nephrologists, it was pre-
sumed that the effect was confined to the glomerulus [9].
Understandably, unlike capillary beds in any other organs, the
glomerulus is linked in series with a post-capillary sphincter,
that is, the efferent arteriole; which allows the glomerular
capillary pressure to be regulated independently of the prevail-
ing systemic blood pressure. Moreover, ACE!, in contrast to
other vasodilators, lead to preferential dilation of this postcap-
illary sphincter and cause a profound fall in glomerular capillary
pressure in models of CRF [2, 4—7]. Thus, if one assumes that
the level of the glomerular pressure determines the progression
of sclerosis, the above presumption appears not at all unrea-
sonable. Studies conducted outside the nephrology field, how-
ever, showed a similar systemic blood pressure-independent,
structure-preserving effect of ACE! [10—18]. Thus, in animal
models of primary hypertension, therapy with ACE! has been
shown to attenuate cardiovascular hypertrophy and hyperplasia
more effectively than other antihypertensive drugs at equipo-
tent pressor doses [10—14]. !n several models of hypertensive
cardiac hypertrophy, ACE! was shown to prevent, or even
cause regression of cardiac hypertrophy independently of their
effect on systemic blood pressure [11—13]. Vascular smooth
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rat chow and tap water for the next eight weeks. As shown in
16 Figure 1, at eight weeks, open renal biopsy of the left remnantw kidney was performed via a midline abdominal incision. A small
portion of the upper pole was removed surgically and bleeding
controlled by application of gelfoam. Animals were then
grouped into treatment groups as specified below and sacrificed
Autopsy at 16 weeks after assessment of renal function. Tissues were
then examined as described below by autopsy, when extra-
renal vasculature was assessed and renal morphology was
compared to biopsy in the same animals. Systolic blood pres-
sure, body weight, BUN and hematocrit were measured every
two weeks. Systolic blood pressure was measured in conscious
state by the tail cuff method [221.
ACEI
Angiotensin II receptor antagonist
Triple therapy
Reserpine
+ Hydrochlorothiazide
+ Hydralazine
Fig. 1. Schematic presentation of the experimental protocol. ACEI
groups include captopril, CPL, enalapril, ENL and lisinopril, LSL.
Triple therapy, TRX, includes reserpine, hydrochlorothiazide and
hydralazine. Angiotensin II receptor antagonist (L-158,809), Ang IIR,
includes low dose and high dose groups.
muscle hypertrophy in extrarenal arteries in spontaneously
hypertensive rats was decreased with ACEL [17], and pretreat-
ment with ACEI or angiotensin receptor antagonist (Ang IIR)
prevented vascular intimal proliferation following balloon cath-
eter injury in vivo [18, 19].
The presence of a postcapillary sphincter may then not be a
prerequisite for ACE! to exert their systemic blood pressure-
independent salutary effect on vascular structure. It remains
uncertain, however, whether CRF develops systemic arterial
wall abnormalities of a nature identical to those of primary
systemic hypertension [20]. Of note, in addition to the effects of
hypertension in CRF, the arterial walls are constantly exposed
to the uremic milieu, With all these concerns in mind, we felt
that assessment of the response to antihypertensives and a
novel Ang II receptor antagonist (Ang IIR, L-158,809) of both
glomerulus and systemic vascular beds in CRF would provide
an opportunity to test whether the blood pressure-independent,
structure-preserving effect of antihypertensives is attributable
to the unique structure of the glomerular efferent arteriole, and
whether such effects are due at least in part to inhibition of Ang
II production. Also, our morphological approach circumvents
recent criticism by some investigators that glomerular capillary
hydraulic pressure measurement is limited to a small number of
investigators and is subjective in nature [21].
Methods
Experiments were performed on 63 adult male Munich-
Wistar rats which weighed 190 to 220 g. All surgery was
performed under anesthesia with sodium pentobarbital (Nem-
butal, 25 to 30 mg/kg body wt, i.p.), except for final functional
studies immediately before sacrifice, when animals received
mactin (100 mg/kg body wt, i.p.). As shown in Figure 1, all rats
underwent subtotal nephrectomy, that is, right nephrectomy
and ligation of two or three branches of left renal artery, leaving
1/6 to 1/8 of total kidney mass, as previously described [2].
After recovery from surgery, rats had free access to standard
Experimental groups
ACE! at a given dose has previously been found to decrease
blood pressure over the course of the first week of therapy to
steady state levels in the model of subtotal nephrectomized
rats. This pilot study, which measured systemic blood pressure
one day before therapy, one day and seven days after therapy,
revealed in triple therapy 178.9 7.7, 106.7 7.4 and 106.1
7.0 mm Hg, respectively, and on the other hand, 175.3 4.7,
157.0 3.9 and 132.0 5.3 mm Hg in ACEIs (P < 0.0005 TRX
vs. ACEIs at first day after treatment, P < 0.005 at seventh
day). Therefore, the dose of ACE! was increased after the first
week to maintain equal control of blood pressure as in TRX
group. Those rats which did not obtain systemic blood pressure
control (<160 mm Hg) with this protocol (N = 7), were then
excluded from further studies. The remaining rats were then
divided into the following groups:
(1) ACEI (captopril, enalapril and lisinopril). These three
groups were treated with equipotent doses of three different
ACEI in terms of equal inhibition of circulating ACE activity
from 8th week to 16th week after subtotal nephrectomy. Previ-
ous studies have shown that the oral doses that were expected
to deliver equivalent levels of ACE inhibitory activity in the
circulation were: captopril (CPL), 30 mg/kg/day; enalapril
(ENL), 20 mg/kg/day; and lisinopril (LSL), 10 mg/kg/day [23].
Thus, doses of CPL, ENL and LSL were given in proportions
by weight of 3:2:1, and the rats were treated with either CPL,
600 mg/liter drinking water (DW) (about 30 mg/kg/day, N = 10);
ENL, 400 mg/liter DW (20 mg/kg/day, N = 9); or LSL, 200
mg/liter DW (10 mg/kg/day, N = 10).
(2) Angiotensin II receptor antagonist group (Ang IIR,
L-158,809, Merck, Sharp & Dohme). These rats were divided
into two subgroups, treated with either "low" dose (20 mg/liter
DW, N = 7) or "high" dose (80 mg/liter DW, N = 5). "Low"
dose was the minimum dose required to decrease systemic
blood pressure in this model. These rats were treated as the
above groups from week 8 to week 16 after subtotal nephrec-
tomy. The Ang hR used is a new angiotensin II type I receptor
antagonist which shows high affinity and selectivity for the type
I receptor with no agonist activity. The drug is orally active
with long-lasting effects, over six hours after a single dose in the
rat [24—26].
(3) TRX group. Rats (N = 10) were treated with reserpine 5
mg/liter DW, hydralazine 80 mg/liter DW and hydrochlorothi-
azide 25 mg/liter DW, a dose previously shown to control
systemic blood pressure but known not to ameliorate the
progression of renal injury [4]. This dosage was chosen to
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differentiate the direct hemodynamic effect and the effect of
uremia on the cardiovascular system. Treatment was started at
8 weeks and continued to 16 weeks after subtotal nephrectomy.
(4) Control group. Previous data show that rats with inade-
quate renal ablation do not develop progressive renal disease.
Rats without hypertension (SBP remained below 160 mm Hg),
no significant uremia and inadequate renal ablation confirmed at
laparotomy for renal biopsy (N = 2), were therefore excluded
from the study. Remaining control rats (N = 6) were treated as
the above groups, except that they received only tap water for
the duration of observation after subtotal nephrectomy.
(5) Age-matched normal group. Twenty-four week old nor-
mal age-matched control rats (N = 6) were sacrificed as above
for morphological examination of extrarenal vasculature.
Glomerular and whole kidney functional studies
Rats were anesthetized at 16 weeks for measurements of
kidney function with an intraperitoneal injection of mactin
(Byk, Gulden Konstanz, Germany; 100 mg/kg body wt), placed
on a temperature-regulated micropuncture table, and prepared
as previously described [27]. Briefly, following tracheostomy,
indwelling polyethylene catheters (PE-50, Clay Adams, Parsip-
pany, New Jersey, USA) were placed into the left jugular vein
for infusion of plasma, inulin and para-aminohippurate (PAH).
Volume losses consequent to surgical preparation were re-
placed with plasma, infused in a volume equal to 1% of body
weight over 30 minutes, followed by a maintenance infusion of
1.2 mi/hr. After a priming dose of 0.5 ml of 0.9% NaCl
containing 5% inulin and 1% PAH, maintenance infusion was
continued through each experiment at a rate of 1.2 mI/hr. The
right carotid artery was cannulated with PE-50 which was
inserted into the left ventricle and pressure was measured by an
electronic transducer (Model p23XL, Gould Inc., Cleveland,
Ohio, USA) connected to a recorder (Model 2200S, Gould
Inc.). The abdomen was incised and the left kidney was
suspended on a Lucite holder, its surface illuminated with a
fiberoptic light source, and bathed with 0.9% NaCI. The left
ureter was cannulated with PE- 10 catheter for urine collections.
After a 30 to 60 minute equilibration period, clearance and
micropuncture measurements were made. Exactly timed (0.5 to
3 mm) samples of tubule fluid were collected from surface
proximal convolutions for the determinations of flow rate and
inulin concentration for calculation of single nephron glomeru-
lar filtration rate (SNGFR) as previously described [271. For the
purpose of this timed fluid collection, mineral oil stained with
Sudan black was injected into proximal tubule with a micropi-
pette with outer diameter of 4 to 8 jsm, and filled by gentle
suction to keep the oil from flowing downstream up to approx-
imately 3 to 5 diameter lengths of the lumen. Coincident with
the tubule fluid collections, arterial blood was obtained for the
determination of hematocrit and plasma concentrations of mu-
un and PAH. Timed collections of urine samples from the
kidney were collected for determination of flow rate and inulin
concentrations, which were used in the calculation of whole
kidney GFR.
Histological study
(1) Glomerulus. Light microscopic studies were performed on
the biopsy (8 weeks) and autopsy (16 weeks) kidney specimens
from the same rat. Tissue was harvested after perfusion speci-
fled below and further immersion fixed in 10% buffered forma-
lin, routinely processed, paraffin embedded and 4 m sections
cut and stained with periodic acid-Schiff. Histological examina-
tion was performed without knowledge of the treatment proto-
col. Glomerular sclerosis was assessed by examining all gb-
meruli on a single section of the kidney, scoring each
gbomerulus from 0 to 4 as described by Raij, Azar and Keane
[281. Thus a 1 + lesion represented sclerosis of up to 25% of
glomerulus, while 4+ represented sclerosis of 75 to 100% of
glomerulus. A whole kidney sclerosis index was obtained by
averaging scores from all glomeruli of one section. A minimum
of 50 glomeruli were analyzed in autopsied kidney and more
than 25 glomeruli were analyzed in biopsy specimens.
(2) Other vasculature. (A.) Heart and coronary artery. To
investigate the vascular change in extrarenal microvasculature,
we studied the intramural branches of the left coronary artery
within the endocardium of posterior portion of the left ventric-
ular free wall [13]. After final clearance studies, adenosine, i0
M diluted with 0.9% saline, was injected via the carotid arterial
catheter for 30 seconds to prevent contraction artifacts of the
vessels. The hearts were then rapidly fixed with 2.5% phos-
phate buffered glutaraldehyde from a catheter inserted into the
left ventricle via right carotid artery at a perfusion pressure of
100 mm Hg for 10 minutes, with cardiac arrest at the dilated
phase. The heart was removed and the atria excised, thus
leaving the ventricles separate. The tissue was then rinsed with
normal saline, weighed, and cross sections were then fixed
further in 10% neutral buffered forinalin and dehydrated by
standard processing in graded ethanol solutions, and embedded
in paraffin. Four-micrometer thick sections were cut and
stained with hematoxylin and eosin, and wall thickness ratio of
coronary arteriole assessed as described below.
(B.) Aorta. After perfusion fixation, a segment of the aorta,
extending 0.5 cm immediately below the left renal artery was
excised and processed as described below.
(C.) Carotid artery. The left carotid artery was removed from
its origin from the common carotid and a 1 cm segment
extending adjacent to the trachea was excised.
(D.) Mesenteric artery. A 0.5 cm long segment starting at the
origin of the superior mesenteric artery was excised.
(E.) Left renal artery. The whole length of left renal artery
was excised. The vessels were embedded perpendicular to their
long axis in low melting point paraffin and 4 m cross sections,
as assessed by symmetric, concentric internal and external
circumferences of the vessel wall, were stained by Masson's
stain.
(3) Determination of thickness of vessel wall. Wall thickening
(muscle layer of artery) ratio was defined as ratio of media
thickness to outer radius of the vessel. Inner and outer circum-
ferences were measured using a computerized planimeter (Mi-
cro-plan 2, Donsanto Corp., Natick, Massachusetts, USA).
Only sections of vessels cut in a plane perpendicular to the long
axis were evaluated. Values were corrected to a circle by
calculating the ratio by the following equation:
where
Wall thickening ratio = (R — r)/R
R = radius of vessel, calculated from outer circumference of
muscle layer
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Body weight
8 weeks 12 weeks 16 weeks
Control 258.7 11.0 294.0 8.2 283.2 19.9
TRX 276.6 7.4 274.0 9.2 244.3 17.2
Captopril 287.2 54a 290.8 8.0 320.6 8.o
Enalapril 280.5 1.1 299.6 11.7 313.8 15.0
Lisinopril 282.7 5.la 293.5 5.4 293.0 14.2
Ang hR (20) 254.9 14.1 284.7 7.2 289.0 13.6
Ang hR (80) 257.0 6.1 276.4 4.9 271.0 14.1
a P < 0.05 vs . control
R — r media thickening
inulin clearance
Urinary and plasma inulin concentration was measured by
the macroanthrone method [29].
Statistical analysis
Results are expressed as means 1 SEM. Comparisons
between two groups were made using the unpaired t-test. Data
from multiple groups were compared using one-way ANOVA
followed by multiple comparisons by Bonferroni method [30].
Comparison of wall thickness ratio and SBP was done by linear
regression analysis. The results were deemed statistically sig-
nificant when P value was < 0.05.
Results
Course of body weight and hematocrit in control, TRX,
ACEIs and Ang hR
As shown in Table 1, body weights of rats at the onset of
therapy at eight weeks after subtotal nephrectomy (sNPX) were
somewhat higher in captopril and lisinopril groups. Over the
next eight weeks, from the eighth to the 16th week after sNPX,
the ACEI and Ang hR treatment groups showed continued
growth, with significantly higher body weight versus control for
CPL and LSL at eight weeks (P <0.025) and CPL only at 16
weeks (P < 0.05). In contrast, the TRX group and control group
showed significant weight loss after 12 weeks compared to the
other groups. Body weight of TRX was less than other treat-
ment groups (P < 0.05 vs. LSL at 12 weeks, P < 0.0005 vs.
CPL, P <0.005 vs. ENL and P < 0.025 vs. LSL at 16 weeks).
Ang hR groups also showed lower body weight than CPL at
eight and 16 weeks (low dose, P < 0.05, and high dose, P <
0.005) and lower than LSL at eight weeks. Hematocrit was
significantly higher in TRX, CPL, ENL versus control at 16
weeks (Table 2, P < 0.01 vs. TRX, P < 0.05 vs. CPL and ENL).
In addition, values of hematocrit in Ang IIR were significantly
less than in other treatment groups (P < 0.05 low dose Ang hR
vs. TRX and CPL at 16 weeks; P < 0.025 high dose Ang hR vs.
CPL, and P < 0.05 high dose Ang hR vs. ENL and LSL).
BUN Hct
8 weeks 16 weeks 8 weeks 16 weeks
Control 57.3 5.5 107.7 25.2 44.8 0.6 41.2 1.7
TRX 53.9 5.4 73.6 4.3 48.4 l.4a 45.8 0.7
Captopril 51.8 3.8 53.7 4.8e 46.7 0.8 45.3 1.la
Enatapril 51.3 4.0 55.8 34a 473 0.9 44.6 1.oa
Lisinopril 55.7 3.5 63.6 6.6a 44.0 1.0 44.0 1.0
Ang hR (20) 47.6 5.2 55.3 10.4 44.5 2.4 40.5 2.1
Ang hR (80)
a P < 0.05 v
51.5±3.7
s. control
70.8 7.3 45.0 1.1 41.0 1.9
Table 3. Alteration of systolic blood pressure from 8 to 16 weeks
Systolic pressure mm Hg
8 weeks 12 weeks 16 weeks
Control
TRX
Captopril
Enalapril
Lisinopril
Ang hR (20)
Ang IIR (80)
________________________________________
NS: TRX vs. ACEI at 8, 12 and 16 weeks, and vs. Ang hR at 8 and
16 weeks
a p < 0.0005 vs. TRX
b P < 0.025 vs. Ang IIR (20, 80)
Systemic blood pressure in control, TRX, ACEIs and
Ang hR
As shown in Table 3, treatment with ACEIs, Ang hR or
TRX, as dictated by the study design, indeed decreased blood
pressure to levels significantly and similarly below untreated
control at 16 weeks (135 mm Hg vs. 180 mm Hg, respectively,
at 16 weeks, treated group means vs. untreated). However,
TRX therapy resulted in prompt decrease in blood pressure to
less than 140 mm Hg, while it took at least one week for ACEIs
to decrease pressure to the same level. In rats in ACEI group in
which blood pressure decreased to the target range, this level
was maintained for the remainder of the observation period. In
contrast, the TRX group, while maintaining decreased blood
pressure until 12 weeks, thereafter showed a gradual increase in
blood pressure. However, SBP was not significantly different
from ACE! throughout the course, except at 10 weeks, when
TRX SBP was significantly lower than AC El. Both of Ang hR
groups showed a similar pattern, but with somewhat higher SBP
at 12 weeks than other groups. The values of SBP in both
groups treated with Ang IIR were significantly more than TRX
(P < 0.0005) and CPL (P < 0.025) at 12 weeks.
Cardiovascular structure
Cardiac mass and coronary arteriole wall. The ratio of
heart/body weight, a parameter of myocardial hypertrophy, was
measured in each group at 16 weeks. As shown in Figure 2,
although blood pressure was decreased similarly in TRX, ACEI
and angiotensin II receptor antagonist, this ratio was lower in
rats treated with lisinopril, captopril or low dose Ang IIR versus
182.5 6.6 190.0 10.0 180.8 8.5
180.6 7.7 131.1 4.0 149.4 8.3
177.0 5.0 131.0 39b 135.0 6.4
183.8 5.1 141.3 6.4 140.6 5.3
189.5 7.0 129.4 7.9 135.0 4.5
204.3 9.7 157.1 15.Y' 148.6 13.5
207.0 17.7 150.0 94a 144.0 9.1
Table 1. Comparison of body weight among therapeutic groups Table 2. Changes of BUN and hematocnt in ACEI, TRX and
untreated group
and
r = radius of lumen, calculated from inner
lumenal circumference
Fig. 2. Comparison of the ratio of heart
weight to body. Captopril, lisinopril and
angiotensin II receptor antagonist treatment
lowered this ratio vs. untreated group,
indicative of attenuation of hypertrophy of
heart. Open bar shows untreated control and
normal age-matched control. Bars show mean
SE . * denotes significant differences (P <
0.05) vs. control and TRX, specific P values
are given in the text. Abbreviations are: TRX,
triple therapy; CPL, captopril; ENL,
enalapril; LSL, lisinopril; Ang hR.
angiotensin II receptor antagonist.
* * * * * *
* * * * * *
Fig. 3. Comparison of the wall thickness ratio
in the branch of left coronary artery. Whereas
triple therapy revealed more severe coronary
artery wall thickening, treatment with ACEIs
and angiotensin II receptor antagonist
ameliorated these changes. Open bar shows
untreated control and normal age-matched
control. Data are expressed as mean SE.
* denotes significant differences (P < 0.005)
vs. control and TRX, specific P values are
given in the text. Abbreviations are: TRX,
triple therapy; CPL, captopril; ENL,
enalapril; LSL, lisinopril; Ang IIR,
angiotensin II receptor antagonist.
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vs. Control * * . *
vs.TRX * * *
6.0
• 50
4.0Lillhl3.02.0t 4C) 1.00
Control TRX CPL ENL LSL Normal Ang hR
low high
vs. Control
vs. TRX
0.5
0.4
0
0.3
(0
C)
C.)
0.1
0.0 I
Control TRX
nil
Ang hR
low high
CPL ENL LSL Normal
TRX or enalapril treated rats, which showed cardiac hypertro-
phy similar to that of untreated control (3.26, 3.62, 3.47, 3.51
and 3.40 for lisinopril, captopril, low or high dose Ang hR and
normal, respectively, vs. 4.82, 4.18 and 4.18 heart/body wt
ratios x 10, respectively, for TRX, enalapril and untreated
control; P < 0.005 control vs. lisinopril, P < 0.05 control vs.
captopril or normal, P < 0.05 TRX vs. captopril, P < 0.025
TRX vs. lisinopril and normal).
Wall thickening (WT) ratio was assessed in smaller resistance
vessels and larger vessels. The effects of ACEI, Ang hR and
TRX on the intramural coronary arteriole (diameter 25 tm)
are shown in Figure 3. In TRX, branches of coronary arteries
developed medial hypertrophy. In contrast, in ACEI and Ang
hR groups, WT was substantially ameliorated (WT ratios 0.388
in control, 0.298 in TRX, 0.117 in captopril, 0.135 in enalapril,
0.130 in lisinopril, 0.112 in low dose of Ang IIR, 0.101 in high
dose of Ang hR and 0.088 in normal rats; P < 0.0005 control vs.
TRX, ACEIs and Ang lIRs, P < 0.0005 TRX vs. captopril, Ang
IIRs and normal, P < 0.005 TRX vs. enalapril or lisinopril, P <
0.025 normal vs. captopril and enalapril, P < 0.0005 normal vs.
control).
Carotid and mesenteric arterial wall. The carotid artery and
mesenteric artery showed the same effects of treatment as the
smaller coronary artery branches. As shown in Figures 4 to 6,
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vs. Control *
* * a * a a
0
4-
Co0,
C.)
-C4-
Fig. 4. Comparison of the wall thickness ratio
in the left carotid artery. As in coronary
artery, ACEIs and angiotensin II receptor
antagonist prevented hypertrophy in carotid
artery, compared with TRX. Open bar shows
untreated control and normal age-matched
control. All data are expressed as mean SE.
* denotes significant differences (P < 0.05) vs.
control and TRX; specific P values are given
in the text. Abbreviations are: TRX, triple
therapy; CPL, captopril; ENL, enalapril;
LSL, lisinopril; Ang hR. angiotensin II
receptor antagonist.
Fig. 5. Comparison of the wall thickness ratio
in the branch of mesenteric artery. TRX had
higher wall thickness ratio than ACEIs and
angiotensin II receptor antagonist. Open bar
shows untreated control and normal age
matched control. All data are expressed as
mean SE. * denotes significant differences
(P < 0.05) vs. control and TRX; specific P
values are given in the text. Abbreviations
are: TRX, triple therapy; CPL, captopril;
ENL, enalapril; LSL, lisinopril; Ang IIR,
angiotensin II receptor antagonist.
in both mesenteric and carotid artery, the TRX group showed
as severe a vessel wall thickening as the untreated control
group. In contrast, all ACE! groups and Ang hR had lower WT
ratios. In carotid artery the ratios were 0.130 in control, 0.118 in
TRX, 0.076 in captopril, 0.071 in enalapril, 0.071 in lisinopril,
0.088 in low dose of Ang hR. 0.075 in high dose of Ang hR and
0.074 in normal. In mesenteric artery the ratios were 0.147 in
control, 0.149 in TRX, 0.101 in captopril, 0.115 in enalapril,
0.099 in lisinopril, 0.117 in low dose of Ang IIR, 0.104 in high
dose of Ang hR and 0.075 in normal (carotid artery; P <0.0005
TRX vs. captopril, enalapril and lisinopril, P < 0.01 TRX vs.
normal, P < 0.05 Ang hR (low) vs. TRX, P < 0.025 Ang hR
(high) vs. TRX, P = NS normal vs. ACEIs, P = NS Ang hR
vs. ACEIs and control vs. TRX; mesenteric artery; P < 0.0005
vs. TRX
* * a
0
4-
U)(00)C
C.,
-C4-
0.2
0.1
0.0
0.2
Control TAX LSL Normal Ang hR
low high
vs. Control * a a a a a
vs.TRX a * a a a a
0.0
Control TAX LSL Normal Ang hR
low high
TRX
Fig. 6. Morphology of carotid artery. Untreated rats, top left panel, and TRX rats, bottom left, show similar marked vessel wall thickening. In
contrast, rats treated with ACEI (represented here by captopril, CPL), bottom right, show vessel walls indistinguishable from normal rats (top
right) (Masson stain, magnification >< 100). Publication of this figure in color is made possible by a grant from Merck, Sharp & Dohme, West Point,
Pennsylvania, USA.
Fig. 8. The morphology of the kidney appears similar in both AJIR treated (middle panel) and ACEI treated (represented by lisinopril, LSL, right
panel), in contrast to severe glomeralosclerosis in antreated rats (No Rx, left panel). (PAS, magnification >( 115). Publication of this figure in color
is made possible by a grant from Merck, Sharp & Dobme, West Point, Pennsylvania. USA.
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Fig. 7. Change of sclerosis index (SI) between 8th week and 16th week.
Each circle represents the percent change of sclerosis index in one rat,
The mean value is indicated with bar. * denotes significant differences(P < 0.05) vs. control and TRX (specific P values are given in the text).
Abbreviations are: TRX, triple therapy; CPL, captopril; ENL, enala-
pril; LSL, lisinopril; Ang hR. angiotensin II receptor antagonist.
TRX vs. captopril, lisinopril and normal, P < 0.01 TRX vs.
enalapril, P < 0.01 normal vs. captopril and lisinopril, P < 0.025
normal vs. enalapril and low Ang hR vs. TRX, P < 0.005 high
Ang hR vs. TRX). Comparison in treatment groups of WT ratio
and BP by linear regression analysis showed no correlation of
these two parameters.
Walls of abdominal aorta and renal artery. These two
arteries showed no significant difference of WT ratios among
the groups. In renal artery, rats showed the following WT
ratios: captopril; 0.207 0.029, enalapril; 0.220 0.044,
hisinopril; 0.210 0.026, TRX; 0.215 0.027 and control; 0.175
0.030. In abdominal aorta, control and TRX group had WT
ratios of 0.125 0.015 and 0.135 0.009, and ACEIs showed
the following ratios, respectively, captopril; 0.149 0.014,
enalapril; 0.151 0.012, lisinopril; 0.140 0.010.
Glomerular sclerosis
Figure 7 shows the alteration of sclerosis index from eighth
week to 16th week after subtotal nephrectomy, expressed as
percent increase over baseline eight-week sclerosis index in
each rat. Sclerosis was similar between groups at the onset of
therapy at eight weeks; 0.66 0.15 in control versus 0.54
0.16, 0.80 0.15, 0.69 0.13, and 0.54 0.13 in TRX,
captopril, enalapril and lisinopril, respectively (P NS). Scle-
rosis in Ang hR groups was 1.21 0.23 and 1.11 0.20,
respectively, in low and high dose groups. However, there was
marked variation in the degree of progression of structural
lesions. In control group, the severity of sclerosis progressed
uniformly, on average by some 458% (range 69% to 1020%)
GFR mI/mm
Control 0.05 0.01
TRX 0.32 0.01*
Captopril 0.67 0. l0
Enalapril 0.38 0.10
Lisinopril 0.36 0.05
Ang hR (20) 0.36 o.o6
Ang hR (80) 0.42 0.06a
Glomerular function
Table 2 shows the change of BUN over the study period.
Mean BUN at 16 weeks was lower in ACE! and Ang hR than
TRX (P <0.005 ACEIs vs. TRX, P < 0.05 low dose of Ang hR
vs. TRX). As shown in Table 4, ACEI, Ang IIR and TRX
treatedgroups had more residual renal function as measured by
whole kidney inulin clearance studies than untreated control
rats, who were in the final stages of uremia at 16 weeks after
sNPX (P <0.0005 control vs. TRX, LSL and high dose Ang
JIR, P < 0.005 control vs. CPL, ENL and low dose Ang IIR, P
<0.025 high dose Ang hR vs. TRX, P < 0.05 CPL and LSL vs.
TRX). Micropuncture assessment of glomerular function imme-
diately before sacrifice showed marked heterogeneity of
SNGFR, as illustrated in Figure 9. This variation was so
marked that significant differences were not detected.
Discussion
To achieve our experimental goal, we chose several vascular
beds for our morphological evaluation to assess effect of
treatment on large arteries (aorta, carotid, renal and mesenteric
artery) and on muscular arteriole of same diameter as the renal
arterioles, that is, coronary intramural arteriole. The specific
sites within each vessel chosen for morphometric analyses were
based on previous studies by others [17] demonstrating minimal
animal-to-animal variability for these sites. Our results also
showed that, as seen previously in many other models [17], the
extent of smooth muscle hypertrophy is variable in different
arteries. Thus, arteries of different size and with different
resistance, depending on their anatomical location, respond
differently in models of hypertension. There might be regional
susceptibility to hypertrophy among the arteries in renal failure
*
*
* * * *
* * *
Table 4. Whole kidney function study at 16 weeksvs. Control *
vs. TAX
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a P < 0.005 vs. control (specific values are in the text)
from biopsy at eight weeks to autopsy at 16 weeks. TRX, as
expected with this dose, had only minor effect on the progres-
• sion of renal injury, with on average 212% increase in sclerosis
index (range 60% to 629%). In contrast, all ACE! treatment
groups showed marked decrease in progressive renal injury,
with many rats showing no further progression or even less
sclerosis at autopsy than at biopsy, possibly indicating regres-
sion of structural injury in these rats. In captopril treated rats,
the sclerosis index increased 46%, with 98% increase in enala-
pril group and 52% increase in lisinopril group (P < 0.025 TRX
vs. hisinopril, P < 0.01 TRX vs. captopril, P < 0.05 control vs.
TRX). Similarly, in Ang IIR groups the sclerosis index in-
creased 34% in low dose group, and 22% in high dose group (P
<0.025 vs. TRX, P = NS Ang IIR vs. ACE!), also with similar
morphologic appearance of glomeruli in Ang HR and ACE!
groups (Fig. 8).
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blood pressure in patients with renal failure may not provide
optimum protection of progressive structural injury to the
cardiovascular system [32].
300 The mechanisms which induce the hypertrophy of renal and
extrarenal vasculature have not been identified, but several
. 200
possibilities merit consideration. Recent research has presented
the concept of localized renin-angiotenin system (RAS) within
arteries [33—36]. Individual organs have been shown to have
organ specific localized RAS with characteristic autocrine and
100 paracrine function [37, 38]. The kidney has an abundant activity
of its RAS, exceeding systemic levels several-fold [39]. Thus,
treatment with a minimum dose of ACE! to afford inhibition of
0
Control TAX CPL ENL LSL
Fig. 9. Single nephron glomerular filtration ratio (GRF) a! 16th week,
Because of the internephron variability, significant differences were
undetectable. The mean value is expressed with bar. Abbreviations are:
TRX, triple therapy; CPL, captopril; ENL, enalapril; LSL, lisinopril.
due to hypertrophy induced primarily by local factors and
possibly local differences in shear stress and force [31]. Our
results support such differences of vessel hypertrophy and
response to therapy, in that the most significant changes and
also most dramatic effects of ACE! therapy, could be seen in
coronary, mesenteric and carotid arteries, whereas renal artery
and aorta showed no effect of treatment, In the present study,
effects of drug therapy on glomerular sclerosis were correlated
closely with effects on non-glomerular cardiovascular structure.
Thus, in the TRX group, where progression of renal injury was
not substantially affected, cardiovascular extrarenal structural
damage likewise was not ameliorated. Even in the TRX rats
with lowest systemic blood pressure, vessels (carotid artery,
mesenteric artery and coronary arteriole) and heart showed
hypertrophy as severe as in untreated control. In contrast, all
groups treated with ACEI or Ang hR showed substantial
benefit on both renal and extrarenal vascular structural injury.
Although the enalapril treated group did not show statistically
salutary effect on the changes in glomerular sclerosis index that
occurred between biopsy and autopsy, this appears to reflect
largely a wide animal-to-animal variability existing at the onset
of therapy (sclerosis index from 0.33 to 1.05). In other ACEI
groups, significant amelioration was seen in the changes of
sclerosis index with even less sclerosis at autopsy than at
biopsy in some rats in each group. In contrast, in TRX treated
group, all rats showed progression of both renal and extrarenal
injury, regardless of severity of sclerosis at onset of therapy
(sclerosis index from 0.07 to 1.13 at biopsy).
It is of interest to consider the wall thickening observed in
this study of CRF and that reported in other hypertensive
models such as SHR [17]. Although differences in methodology
limit direct comparison of absolute values, the magnitude of
WT ratio appears markedly less in SHR, with coronary arteriole
WT ratio only 1.5 times control, in contrast to the fourfold
increase seen in this study with CRF coronary arteriole. These
differences point to the possibility that the structural changes of
extrarenal arteries and heart occurring in CRF may not be of a
nature identical to that in primary hypertension, but may have
component(s) attributed to uremia per Se. Clinically, these
findings suggest the possibility that merely control of systemic
systemic, that is, circulating levels of ACE may not inhibit local
RAS activities. In this regard, the dose of enalapril most
commonly used in animal studies (50 mg/literdrinking water), is
known to inhibit systemic ACE, and yet far more dramatic
effects on renal structural injury are evident with higher doses
of ACEI [31, possibly due to greater effects on intrarenal RAS.
Local RAS has also been postulated to play a key role to induce
vascular smooth muscle cell hypertrophy [31].
Angiotensin II causes increased mesangial matrix production
and hypertrophy of mesangial cells in culture [40], and inhibi-
tion of angiotensin II formation by ACEI and recently by Ang II
receptor antagonist [19], and has been shown to inhibit vascular
smooth muscle hypertrophy or proliferation in vivo [17, 19].
ACEI also inhibits the glomerular hypertropy which otherwise
is linked to the subsequent development of excess mesangial
matrix and glomerular sclerosis [21. In addition, particularly in
the model of cardiac hypertrophy, the protooncogenes, c-fos
and c-myc are known to be expressed before discernible mor-
phological change [311, and angiotensin II has been shown in
vitro to induce c-fs expression in aortic smooth muscle cells
[41]. Of note, in our study, a potential trigger of such increased
protooncogene expression, namely elevated systemic blood
pressure, was controlled with TRX, yet extrarenal vascular
hypertrophy developed proportionally with the progression of
renal injury. Thus, it is plausible that ACE! directly inhibits the
localized RAS within both renal and extrarenal vasculature,
thus inhibiting subsequent vascular smooth muscle cell and
mesangial hypertrophy.
Treatment with angiotensin II receptor antagonist, adminis-
tered orally in an equipotent pressor dose to ACE!, resulted in
amelioration of progression of glomerulosclerosis and vascular
hypertrophy comparably to that seen with treatment with
ACE!. Higher doses of Ang hIR, although affording comparable
systemic blood pressure effects as low dose, had even further
beneficial effects on structure. This marked amelioration in
comparison with TRX treatment was in spite of numerically
higher SBP in Ang hR groups throughout the course.
Thus, structural changes not only of glomerular, but also of
systemic vasculatures develop in chronic renal failure and
respond to ACEI and Ang IIR, but less to TRX, even with
adequate blood pressure control. The results from this in vivo
study therefore support the notion that ACE! and Ang IIR have
a property to prevent glomerular sclerosis independently of
their depressive effect on systemic or local (glomerular) pres-
sure. The similar results with Ang I!R and ACEI further
indicate that ACE!'s structure-preserving effect stems from its
specific inhibitory effect on Ang hR synthesis.
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